Form 4: Neurogene Inc. Director Cory S. Freedland Acquires Stock Options

Director Cory S. Freedland of Neurogene Inc. [NGNE] was granted stock options to purchase 7,700 shares of common stock on June 14, 2024.

Summary

• On June 14, 2024, Cory S. Freedland, a director of Neurogene Inc., was granted stock options.
• These options allow Freedland to purchase 7,700 shares of Neurogene's common stock at an exercise price of $42.59 per share.
• The options vest on the earlier of June 14, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon Freedland's continued service to Neurogene.
• Following this transaction, Freedland directly owns options for 7,700 shares of Neurogene's common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders. There are no red flags or negative information in the document.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning the interests of employees and directors with the long-term success of the company. This is a standard incentive mechanism.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely use stock options as part of their compensation strategy.
• The vesting schedule of one year or the next annual meeting is fairly standard.
• The number of shares granted is dependent on the size and stage of the company, and the role of the individual.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to increase the value of their options.

Key Dates